JAMA · 1972 · 18 citations · 6 references
Life SciencesPharmacologyPharmacotherapyAutoimmunityHypersensitivityRheumatologyAutoantibodiesAutoimmune HypersensitivityAutoimmune Rheumatic DiseasesDrug AllergyHypersensitivity ReactionsSystemic Lupus ErythematosusAntibodiesAntinuclear Antibody PositivityDrug-induced Hypersensitivity SyndromeHydralazine TherapyHypersensitivity Reactions To Therapeutic AntibodiesProcainamide TherapySystemic Lupus Erythematosus Associations
<h3>To the Editor.—</h3> Drugs that have been reported to activate systemic lupus erythematosus (SLE) can be divided into those that do so by their own pharmacologic properties, and thus cause it in a considerable percentage of individuals who receive them (hydralazine hydrochloride, isoniazid, procainamide hydrochloride, and various anticonvulsants), and drugs that apparently do it by causing allergic reactions which in turn trigger SLE.<sup>1</sup> One common denominator of drugs that act on their own is that they elicit antinuclear antibodies (ANA) in an even larger percentage of individuals taking them on a long-term basis.<sup>2-4</sup> Activation of SLE by propylthiouracil (PTU) has been described on at least three occasions.<sup>5-7</sup>These reports suggest that this drug might have lupus-activating properties of its own. We have, therefore, investigated the presence and specifity of ANA in the serum of 46 patients (34 females) undergoing long-term PTU treatment by means of a microcomplement
6
D Alarcón-Segovia · BMJ · 1970 · 143 citations · Full text
Procainamide‐induced serologic changes in asymptomatic patients
Javier Molina, Edmund L. Dubois, MICHAEL BILITCH et al. · Arthritis & Rheumatism · 1969 · 60 citations